Cargando...
Loncar Cancer Immunotherapy ETF (CNCR)
Equity · Estados Unidos
Posiciones
Las 31 mayores posiciones de CNCR de 31 en total, a 2026-09-08. La cartera es del fondo, no de esta línea concreta: es la misma en todos los mercados donde cotiza.
Peso de las mostradas
100%
En compañías con ficha
77,21%
Posiciones del fondo
31
| # | Posición | Peso |
|---|---|---|
| 1 | Instil Bio, Inc.TIL | 3,59% |
| 2 | Replimune Group, Inc.REPL | 3,54% |
| 3 | Iovance Biotherapeutics, Inc.IOVA | 3,47% |
| 4 | Zymeworks Inc.ZYME | 3,45% |
| 5 | argenx SEARGX | 3,42% |
| 6 | Genmab A/SGMAB | 3,42% |
| 7 | AstraZeneca PLCAZN | 3,39% |
| 8 | CRISPR Therapeutics AGCRSP | 3,39% |
| 9 | Bristol-Myers Squibb CompanyBMY | 3,39% |
| 10 | Nektar TherapeuticsNKTR | 3,37% |
| 11 | Merck & Co., Inc.MRK | 3,37% |
| 12 | Xencor, Inc.XNCR | 3,37% |
| 13 | Regeneron Pharmaceuticals, Inc.REGN | 3,36% |
| 14 | Gilead Sciences, Inc.GILD | 3,33% |
| 15 | Fate Therapeutics, Inc.FATE | 3,33% |
| 16 | Arcus Biosciences, Inc.RCUS | 3,32% |
| 17 | Atara Biotherapeutics, Inc.ATRA | 3,3% |
| 18 | Trillium Therapeutics Inc.TRIL | 3,29% |
| 19 | Allogene Therapeutics, Inc.ALLO | 3,29% |
| 20 | Rubius Therapeutics, Inc.RUBY | 3,29% |
| 21 | bluebird bio, Inc.BLUE | 3,28% |
| 22 | ImmunityBio, Inc.IBRX | 3,28% |
| 23 | I-MabIMAB | 3,25% |
| 24 | IGM Biosciences, Inc.IGMS | 3,23% |
| 25 | Shattuck Labs, Inc.STTK | 3,23% |
| 26 | ALX Oncology Holdings Inc.ALXO | 3,21% |
| 27 | Legend Biotech CorporationLEGN | 3,2% |
| 28 | BeiGene, Ltd.BGNE | 3,19% |
| 29 | MacroGenics, Inc.MGNX | 3,17% |
| 30 | Y-mAbs Therapeutics, Inc.YMAB | 3,12% |
| 31 | ?Cash&Other | 0,13% |
Las posiciones subrayadas llevan a su ficha: son compañías que cubrimos con datos propios.